ncbi.nlm.nih.gov/pubmed/21353179
Here is some recent findings that shows that Zometa has anti cancer effects for a variety of advanced cancers,bone secondaries or not,including breast cancer.This may be of some interest for those woman who DO NOT have bone secondaries and are looking for other options to help stop disease progression.
I have been receiving 4mg of Zometa every 6 months as a result of these findings.I have lung secondaries only,and im currently NED.I hope the Zometa can help me stay that way.
2x
Thanks for the info, I remember reading something about Zometa’s anti-cancer effects when I went on the drug three years ago but I can’t remember where I saw it.
Sue
Does Bondronat do the same??? My veins are pretty knackered so I opted for the tablets. I am not Her2+ or anything like that so don’t have regular IV treatments and thought tablets would be better for me. They certainly seem to be keeping my bone mets under control.
Sue x
This article relates to Zometa but when I heard about it (from my boss who was busy searching the net in 2008), it was all bisphosphonate drugs.
Just looked up bisphos and anti cancer effects and found this:-
In addition, preclinical studies have shown that bisphosphonates, especially potent nitrogen-containing bisphosphonates, have direct anticancer actions.
Looked up the structure of Bondronate and it contains nitrogen.
Link
breastcancercare.org.uk/forum/posting.php?mode=reply&f=94&t=30857
It was just a quick look so I think you will be able to find more references.
Sue x
Novartis announced in dec2010 that they will not be applying for Zometa to be licenced in an adjuvant primary BC treatment setting after the AZURE study did not confirm previous results from the ABCSG-12 phase 3 trial. This was announced last dec at the San Antonio symposium. Only a small subgroup of well established post menopausal women seem to benefit from Zometa in a primary BC adjuvant setting. This does not affect Zometa in secondaries treatment or other bone loss related treatments. The leading UK expert on the subject is Dr R Coleman in Sheffield. There is a current clinical trial run by him to further evaluate Prolia/denosumab/xgeva in the primary adjuvant setting. You can find details of the trial on the CRUK website on their clinical trial section.